- Home
- CBAT vs ABOS Comparison
CBAT vs ABOS Comparison
Compare CBAT & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAT
- ABOS
- Stock Information
- Founded
- CBAT 1999
- ABOS 1996
- Country
- CBAT China
- ABOS United States
- Employees
- CBAT N/A
- ABOS N/A
- Industry
- CBAT Industrial Machinery/Components
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- CBAT Miscellaneous
- ABOS Health Care
- Exchange
- CBAT Nasdaq
- ABOS Nasdaq
- Market Cap
- CBAT 71.6M
- ABOS 76.9M
- IPO Year
- CBAT N/A
- ABOS 2021
- Fundamental
- Price
- CBAT $0.73
- ABOS $0.99
- Analyst Decision
- CBAT
- ABOS Strong Buy
- Analyst Count
- CBAT 0
- ABOS 3
- Target Price
- CBAT N/A
- ABOS $7.33
- AVG Volume (30 Days)
- CBAT 158.7K
- ABOS 215.3K
- Earning Date
- CBAT 03-17-2025
- ABOS 03-27-2025
- Dividend Yield
- CBAT N/A
- ABOS N/A
- EPS Growth
- CBAT N/A
- ABOS N/A
- EPS
- CBAT 0.13
- ABOS N/A
- Revenue
- CBAT $176,614,609.00
- ABOS N/A
- Revenue This Year
- CBAT $28.79
- ABOS N/A
- Revenue Next Year
- CBAT $36.77
- ABOS N/A
- P/E Ratio
- CBAT $5.67
- ABOS N/A
- Revenue Growth
- CBAT N/A
- ABOS N/A
- 52 Week Low
- CBAT $0.71
- ABOS $0.98
- 52 Week High
- CBAT $2.08
- ABOS $4.06
- Technical
- Relative Strength Index (RSI)
- CBAT 29.57
- ABOS 29.79
- Support Level
- CBAT $0.71
- ABOS $1.14
- Resistance Level
- CBAT $0.90
- ABOS $1.28
- Average True Range (ATR)
- CBAT 0.05
- ABOS 0.10
- MACD
- CBAT -0.01
- ABOS -0.01
- Stochastic Oscillator
- CBAT 8.95
- ABOS 1.54
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.